Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Oncoinvent ASA ( (BRRGD) ) is now available.
Oncoinvent will present final 24‑month data from its RAD‑18‑001 Phase 1 study of Radspherin after cytoreductive surgery in patients with platinum‑sensitive epithelial ovarian cancer with peritoneal recurrence at the ESGO 2026 congress in Copenhagen. The intraperitoneal alpha‑emitting therapy, based on radium‑224‑labelled microparticles, is designed to eliminate residual cancer cells in the peritoneal cavity while sparing healthy tissue.
The Phase 1 study enrolled 21 patients across dose levels and showed a favourable safety profile with no dose‑limiting toxicities and no grade 3 or higher adverse events attributed to Radspherin. At the recommended 7 MBq dose, 9 of 10 patients remained free from peritoneal recurrence at 24 months, supporting a durable local disease control signal and underpinning the company’s ongoing Phase 2 ovarian cancer trial.
The data presentation at a leading gynecologic oncology forum reinforces clinical interest in Radspherin as a potential new standard of care for high‑risk ovarian cancer patients with poor prognosis. Positive early safety and efficacy signals, combined with scalable manufacturing and existing pharma interest, strengthen Oncoinvent’s positioning in the radiopharmaceuticals space and could be significant for future commercial and partnering prospects.
More about Oncoinvent ASA
Oncoinvent ASA is a Norwegian biotechnology company developing Radspherin, a receptor-independent alpha radiation therapy designed to eradicate residual micrometastases in the abdominal cavity after cancer surgery. The company initially targets ovarian and colorectal cancers with intraperitoneal delivery, aiming to prevent or delay peritoneal recurrence while integrating seamlessly into existing surgical workflows and offering scalable, cost-effective manufacturing.
Average Trading Volume: 16,152
Current Market Cap: NOK189.3M
For detailed information about BRRGD stock, go to TipRanks’ Stock Analysis page.